Scholarlink

Objective <p>The current study aims to understand potential disparities in the time to treatment initiation among individuals diagnosed with one of the four most common cancers in the United States and dissect potential changes in time to treatment over time.</p> Methods <p>The Surveillance, Epidemiology, and End Results (SEER) database was accessed, and cases with a primary diagnosis of lung, colorectal, breast, or prostate cancer and a known time between diagnosis and treatment initiation were reviewed. Frequency analyses to examine mean time to treatment initiation across different years within each cancer type were performed, and multivariable logistic regression analyses were then conducted to evaluate factors associated with longer time to treatment within each cancer type.</p> Results <p>For each of the four cohorts, diagnosis in the year 2021 was associated with the longest mean time to start treatment (47.49 days for the lung cancer cohort; 26.38 days for the colorectal cancer cohort; 44.61 days for the breast cancer cohort; 82.75 days for prostate cancer cohort). Within multivariable logistic regression analysis, non-white race was associated with longer time to treatment in each of the studied cancers; for lung cancer cohort: (OR black vs. white race: 1.254 (95% CI: 1.213–1.296); OR Asian/Pacific Islander vs. White race 1.168 (95% CI: 1.125–1.213)); for colorectal cancer cohort: (OR Black vs. white race: 1.057 (95% CI: 1.021–1.094); OR American Indian vs. White race 1.191 (95% CI: 1.068–1.327); OR Asian/Pacific Islander vs. White race 1.117 (95% CI: 1.076–1.159)); for breast cancer cohort (OR for black vs. white race: 1.155 (95%CI: 1.128–1.184)); OR for American Indian vs. White race: 1.134 (95% CI: 1.037–1.241)); OR for Asian/Pacific Islander vs. White race: 1.092 (95% CI: 1.065–1.119)); for prostate cancer cohort <i>(</i>(OR black race vs. white race: 1.239 (95% CI: 1.196–1.285)); OR Asian/Pacific Islander vs. white race: 1.219 (95% CI: 1.157–1.284)).</p> Conclusions <p>Cancer patients with non-white race are likely to have a delayed time to initiation of treatment, across major cancer types in the United States. This disparity was maintained even during the COVID-19 pandemic-related healthcare system distress.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disparities in time to Treatment Initiation Among Patients with Major Types of Cancer in the United States

  • 期刊论文

  • 发表日期：

    2026年1月27日

查看全文
  • Omar Abdel-Rahman,
  • Sunita Ghosh

摘要

Objective

The current study aims to understand potential disparities in the time to treatment initiation among individuals diagnosed with one of the four most common cancers in the United States and dissect potential changes in time to treatment over time.

Methods

The Surveillance, Epidemiology, and End Results (SEER) database was accessed, and cases with a primary diagnosis of lung, colorectal, breast, or prostate cancer and a known time between diagnosis and treatment initiation were reviewed. Frequency analyses to examine mean time to treatment initiation across different years within each cancer type were performed, and multivariable logistic regression analyses were then conducted to evaluate factors associated with longer time to treatment within each cancer type.

Results

For each of the four cohorts, diagnosis in the year 2021 was associated with the longest mean time to start treatment (47.49 days for the lung cancer cohort; 26.38 days for the colorectal cancer cohort; 44.61 days for the breast cancer cohort; 82.75 days for prostate cancer cohort). Within multivariable logistic regression analysis, non-white race was associated with longer time to treatment in each of the studied cancers; for lung cancer cohort: (OR black vs. white race: 1.254 (95% CI: 1.213–1.296); OR Asian/Pacific Islander vs. White race 1.168 (95% CI: 1.125–1.213)); for colorectal cancer cohort: (OR Black vs. white race: 1.057 (95% CI: 1.021–1.094); OR American Indian vs. White race 1.191 (95% CI: 1.068–1.327); OR Asian/Pacific Islander vs. White race 1.117 (95% CI: 1.076–1.159)); for breast cancer cohort (OR for black vs. white race: 1.155 (95%CI: 1.128–1.184)); OR for American Indian vs. White race: 1.134 (95% CI: 1.037–1.241)); OR for Asian/Pacific Islander vs. White race: 1.092 (95% CI: 1.065–1.119)); for prostate cancer cohort ((OR black race vs. white race: 1.239 (95% CI: 1.196–1.285)); OR Asian/Pacific Islander vs. white race: 1.219 (95% CI: 1.157–1.284)).

Conclusions

Cancer patients with non-white race are likely to have a delayed time to initiation of treatment, across major cancer types in the United States. This disparity was maintained even during the COVID-19 pandemic-related healthcare system distress.